Artivion (NYSE:AORT) EVP Lance Berry Sells 4,981 Shares of Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,981 shares of Artivion stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $187,235.79. Following the transaction, the executive vice president directly owned 148,450 shares of the company’s stock, valued at $5,580,235.50. The trade was a 3.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Artivion Price Performance

NYSE:AORT traded up $0.98 during mid-day trading on Thursday, hitting $36.76. 30,985 shares of the stock traded hands, compared to its average volume of 389,761. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The company has a market cap of $1.76 billion, a PE ratio of 183.81 and a beta of 1.59. The business’s 50-day moving average price is $42.27 and its 200 day moving average price is $43.08.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue was up 19.2% on a year-over-year basis. On average, analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Analyst Ratings Changes

Several brokerages have recently commented on AORT. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Canaccord Genuity Group decreased their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Summit Partners Public Asset Management LLC purchased a new stake in shares of Artivion during the fourth quarter valued at approximately $39,401,000. Invesco Ltd. raised its holdings in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC purchased a new stake in Artivion during the 3rd quarter valued at $17,912,000. Goldman Sachs Group Inc. grew its holdings in Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after acquiring an additional 317,518 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Artivion by 235.5% in the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after acquiring an additional 313,446 shares during the period. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.